New hope for transplant patients: daily IL-2 shots may tame chronic GVHD
NCT ID NCT01366092
First seen Nov 01, 2025 · Last updated Jun 06, 2026 · Updated 27 times
Summary
This study tests whether a daily low-dose injection of IL-2 can help control chronic graft-versus-host disease (cGVHD) in 35 adults who have not responded to steroids after a stem cell transplant. cGVHD occurs when donor immune cells attack the patient's body. The treatment aims to calm this immune attack and allow steroid doses to be reduced. The main goal is to see how many patients experience improvement or resolution of cGVHD symptoms after 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02214, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.